Other at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's other?
- Esperion Therapeutics (ESPR) reported other of $2.5M in Q4 2025.
- How has Esperion Therapeutics's other changed year-over-year?
- Esperion Therapeutics's other increased by 16.3% year-over-year, from $2.15M to $2.5M.
- What is the long-term trend for Esperion Therapeutics's other?
- Over 5 years (2020 to 2025), Esperion Therapeutics's other has grown at a -13.1% compound annual growth rate (CAGR), from $5.05M to $2.5M.
- What does other mean?
- This category captures miscellaneous deferred tax assets that do not fall into primary classifications such as net operating losses or specific credit carryforwards. It includes various temporary differences arising from accounting adjustments, accruals, or other tax-specific treatments. Monitoring this helps investors understand the breadth of the company's tax planning and deferred tax position.